Abstract:Proteolysis targeting chimeras (PROTACs) have recently emerged as promising therapeutic agents for cancer therapy. However, their clinical application is considerably hindered by the poor membrane permeability and insufficient tumor distribution of PROTACs. Here we proposed a nanoengineered targeting strategy to construct a self-assembled affibody-PROTAC conjugate nanomedicine (APCN) for tumor-specific delivery of PROTACs. As proof of concept, a hydrophobic PROTAC MZ1 (a bromodomain-containing protein 4 degrader) was selected to couple with a hydrophilic affibody ZHER2:342 (an affinity protein of human epidermal growth factor receptor 2, HER2) via a smart linker containing disulfide bond to form an amphiphilic ZHER2:342-MZ1 conjugate. It spontaneously self-assembled into nanoparticles (ZHER2:342-MZ1 APCN) in water. Upon the excellent targeting property of ZHER2:342 and HER2 receptor-mediated endocytosis, ZHER2:342-MZ1 APCN was accumulated in tumor sites and internalized by cancer cells effectively in vitro. Under the intracellular high level of glutathione (GSH), ZHER2:342-MZ1 APCN released MZ1 to specifically degrade bromodomain-containing protein 4 (BRD4) and subsequently induced BRD4 deficiency-mediated apoptosis of cancer cells. By the tail-vein injection, ZHER2:342-MZ1 APCN showed the outstanding tumor-specific targeting ability, drug accumulation capacity, enhanced BRD4 degradation and antitumor efficacy in vivo for an HER2-positive SKOV-3 tumor model. Such an affibody mediated nanoengineered strategy would facilitate the application of PROTACs for targeted cancer therapy.

Rücktitelbild: Aptamer‐PROTAC Conjugates (apcs) for Tumor‐Specific Targeting in Breast Cancer (angew. Chem. 43/2021)

Back Cover: Aptamer‐PROTAC Conjugates (apcs) for Tumor‐Specific Targeting in Breast Cancer (angew. Chem. Int. Ed. 43/2021)

Aptamer-PROTAC Conjugates (APCs) for Tumor-specific Targeting in Breast Cancer.

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy

Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy

Innentitelbild: Peptide‐Conjugated Long‐Lived Theranostic Imaging for Targeting GRPr in Cancer and Immune Cells (angew. Chem. 41/2020)

Innentitelbild: Bioinspired Engineering of a Multivalent Aptamer‐Functionalized Nanointerface to Enhance the Capture and Release of Circulating Tumor Cells (angew. Chem. 8/2019)

Recent Advances in the Design and Development of Anticancer Molecules Based on PROTAC Technology.

PROTAC: A Promising Technology for Cancer Treatment

A Self-Assembled Affibody-Protac Conjugate Nanomedicine for Targeted Cancer Therapy

PROTAC-biomacromolecule conjugates for precise protein degradation in cancer therapy: A review

Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras Through Irgd Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

PROTACs: Novel tools for improving immunotherapy in cancer

Small-Molecule PROTACs for Cancer Immunotherapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future